Literature DB >> 25962543

Chronic Pain and Decreased Opioid Efficacy: An Inflammatory Link.

Sarah E Giron1, Charles A Griffis2, Joseph F Burkard3.   

Abstract

Chronic pain is a devastating amalgam of symptoms that affects millions of Americans at tremendous cost to our healthcare system and, more importantly, to patients' quality of life. Literature and research demonstrate that neuroimmune cells called glia are not only responsible for initiating and maintaining part of the chronic pain disease process, but also release inflammatory molecules responsible for decreasing the efficacy of one of the most prominent treatments for pain, opioid analgesia. This article describes chronic pain as a disease process that has ineffective treatment modalities, explores the mechanisms of glial cell activation and inflammatory responses that lead to chronic pain and decreased opioid treatment efficacy, and hypothesizes novel chronic pain treatment modalities based on the glial cell inactivation and anti-inflammatory pathways.
Copyright © 2015 American Society for Pain Management Nursing. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25962543     DOI: 10.1016/j.pmn.2015.04.001

Source DB:  PubMed          Journal:  Pain Manag Nurs        ISSN: 1524-9042            Impact factor:   1.929


  3 in total

Review 1.  A Pharmacological Rationale to Reduce the Incidence of Opioid Induced Tolerance and Hyperalgesia: A Review.

Authors:  Giustino Varrassi; Mariella Fusco; Stephen D Skaper; Daniele Battelli; Panagiotis Zis; Stefano Coaccioli; Maria Caterina Pace; Antonella Paladini
Journal:  Pain Ther       Date:  2018-03-28

2.  The Contribution of the Descending Pain Modulatory Pathway in Opioid Tolerance.

Authors:  Lindsay M Lueptow; Amanda K Fakira; Erin N Bobeck
Journal:  Front Neurosci       Date:  2018-11-27       Impact factor: 4.677

3.  Lack of Efficacy: When Opioids Do Not Achieve Analgesia from the Beginning of Treatment in Cancer Patients.

Authors:  Oscar Corli; Giovanna Damia; Francesca Galli; Carmen Verrastro; Massimo Broggini
Journal:  Cancer Manag Res       Date:  2019-12-10       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.